Minsheng Securities released a research report on April 25 stating that Huisheng Biotech (300871.SZ) was given a recommended rating. The main reasons for the rating include: 1) the slump in the farming market affects the company's performance, and the low utilization rate of new construction projects raises initial costs; 2) fixed increases send a positive signal, demonstrating the confidence of actual controllers in future development; 3) putting effort into R&D and innovation, and completing the production capacity layout for core raw materials. (Mainichi Keizai Shimbun)
民生证券4月25日发布研报称，给予回盛生物（300871.SZ）推荐评级。评级理由主要包括：1）养殖行情低迷影响公司业绩，新建项目低利用率拉高初期成本；2）定增传递积极信号，彰显实控人对未来发展信心；3）施力研发创新，核心原料产能布局完成。（每日经济新闻）
Minsheng Securities released a research report on April 25 stating that Huisheng Biotech (300871.SZ) was given a recommended rating. The main reasons for the rating include: 1) the slump in the farming market affects the company's performance, and the low
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.